0001439222-24-000012.txt : 20240124 0001439222-24-000012.hdr.sgml : 20240124 20240124161923 ACCESSION NUMBER: 0001439222-24-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240120 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Milanova Tsveta CENTRAL INDEX KEY: 0001957180 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 24556716 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 88 SIDNEY SREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wk-form4_1706131154.xml FORM 4 X0508 4 2024-01-20 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001957180 Milanova Tsveta C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Commercial Officer 1 Common stock 2024-01-20 4 M 0 5448 0 A 14852 D Common stock 2024-01-24 4 S 0 1618 21.64 D 13234 D Performance share units 2024-01-20 4 M 0 5448 0 D Common stock 5448 0 D Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023. Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The PSUs were granted on January 3, 2023. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. /s/ William Cook, as Attorney in Fact for Tsveta Milanova 2024-01-24